title: Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy.
abstract: Cabergoline (CAB), a new long-acting ergoline derivative, was shown to be very effective in reducing PRL levels in normal volunteers and in hyperprolactinemic patients. We evaluated the hormonal changes after discontinuation of long-term therapy with CAB as well as the safety of drug exposure during pregnancy both for mothers and babies. We therefore studied 48 patients (47 females and one male) with pathological hyperprolactinaemia (mean +/- SE, 117.2 +/- 15.2: median 73.2 micrograms/l), treated for 1-82 months (mean +/- SE, 28.3 +/- 3; median 18). After long-term treatment, CAB was withdrawn in 11 patients and PRL levels were persistently normal for almost 15 days and significantly lower (p < 0.05) than basal at 30, 45, 60, 90, 120 days. Three patients had normal PRL levels still at 45 days after treatment discontinuation. Nine patients became pregnant after 1-37 months (mean 12.4) of therapy. In two patients the pregnancy was interrupted spontaneously in one case and voluntarily in the other. In all but one patients after delivery or three-month breast feeding, PRL levels trended towards reduction. In two cases (one with microadenoma and one with idiopathic hyperprolactinaemia) PRL remained in the normal levels for 1-3 years after delivery. In conclusion CAB is able to inhibit plasma PRL levels for long time (up to 120 days) after withdrawal in patients with pathological hyperprolactinaemia treated with long-term therapy.
authors.affiliation: Dipartimento di Medicina Interna, Università di Torino, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Ciccarelli
authors.forename: S
authors.initials: S
authors.lastname: Grottoli
authors.forename: P
authors.initials: P
authors.lastname: Razzore
authors.forename: D
authors.initials: D
authors.lastname: Gaia
authors.forename: A
authors.initials: A
authors.lastname: Bertagna
authors.forename: S
authors.initials: S
authors.lastname: Cirillo
authors.forename: T
authors.initials: T
authors.lastname: Cammarota
authors.forename: M
authors.initials: M
authors.lastname: Camanni
authors.forename: F
authors.initials: F
authors.lastname: Camanni
mesh_terms: D000236:Adenoma / Q000150:complications / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004873:Ergolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy* / Q000209:etiology; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000150:complications / Q000188:drug therapy*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy; D011256:Pregnancy Outcome; D011388:Prolactin / Q000097:blood
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D011388:Prolactin; D000077465:Cabergoline